Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.69 |
| ▸ | TEK | Q02763 | 5/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.69 |
| ▸ | KIT | P10721 | 8/20 | 0.64 |
| ▸ | ABL1 | P00519 | 3/20 | 0.60 |
| ▸ | BCR | P11274 | 3/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.54 |
| ▸ | CSF1R | P07333 | 4/20 | 0.52 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969584 | 0.89 | LCK (0.55) | LCKTEKKDRKITABL1 | |
| SCHEMBL2966750 | 0.85 | LCK (0.85) | LCKTEKKDRKITABL1 | |
| SCHEMBL2974476 | 0.84 | TEK (0.59) | LCKTEKKDRKITABL1 | |
| SCHEMBL2969534 | 0.82 | LCK (1.00) | LCKTEKKDRKITABL1 | |
| SCHEMBL2972543 | 0.82 | LCK (0.65) | LCKTEKKDRKITABL1 | |
| SCHEMBL2973990 | 0.81 | KIT (0.61) | LCKTEKKDRKITABL1 | |
| SCHEMBL2970078 | 0.81 | LCK (0.71) | LCKTEKKDRKITABL1 | |
| SCHEMBL13220015 | 0.81 | ABL1 (0.55) | LCKTEKKDRKITABL1 | |
| SCHEMBL2976092 | 0.80 | LCK (0.86) | LCKTEKKDRKITABL1 | |
| SCHEMBL2965785 | 0.80 | LCK (0.58) | LCKTEKKDRKITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802586-B1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2013-04-24 | — | — | EP | claimed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. | 2006-09-28 | — | — | US | claimed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | LCK 108/4885TEK 608/4885KDR 666/4885 |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | IRAK3, IRAK1, MAP3K1 | LCK 108/4885TEK 608/4885KDR 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.